Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$122.33 USD
-2.56 (-2.05%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $122.38 +0.05 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Company Summary
Cambridge, MA-based Sarepta Therapeutics is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting DMD, a rare genetic disorder affecting children (primarily males). DMD is the most common type of muscular dystrophy.
Sarepta entered the DMD market with the launch of Exondys 51 (eteplirsen) in 2016 to treat exon 51 skipping DMD. The company also markets three other DMD products. In December 2019, the FDA approved Vyondys 53 (golodirsen) for treating exon 53 skipping DMD. In February 2021, the company ...
Company Summary
Cambridge, MA-based Sarepta Therapeutics is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting DMD, a rare genetic disorder affecting children (primarily males). DMD is the most common type of muscular dystrophy.
Sarepta entered the DMD market with the launch of Exondys 51 (eteplirsen) in 2016 to treat exon 51 skipping DMD. The company also markets three other DMD products. In December 2019, the FDA approved Vyondys 53 (golodirsen) for treating exon 53 skipping DMD. In February 2021, the company received approval for Amondys 45 (casimersen) for treating exon 45 skipping DMD. The company is conducting confirmatory studies to gain continued approval for all three drugs. Sarepta also markets Elevidys (SRP-9001), the first and currently the only gene therapy for DMD, which is approved for treating all DMD patients aged four years and older (regardless of ambulation status), with a confirmed mutation in the DMD gene.
The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051, and a Limb-girdle muscular dystrophy (LGMD) candidate, SRP-9003. Sarepta is also developing gene therapies for treating central nervous system (CNS) disorders, including Mucopolysaccharidosis type IIIA (MPS IIIA) and Pompe Disease.
In 2023, the company’s revenues were $1.24 billion, up 33% year over year.
General Information
Sarepta Therapeutics, Inc
215 FIRST STREET SUITE 415
CAMBRIDGE, MA 02142
Phone: 617-274-4000
Fax: 425-354-5038
Email: iestepan@sarepta.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.14 |
Current Year EPS Consensus Estimate | 1.45 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 124.89 |
52 Week High | 173.25 |
52 Week Low | 55.25 |
Beta | 0.82 |
20 Day Moving Average | 755,787.81 |
Target Price Consensus | 196.94 |
4 Week | -8.02 |
12 Week | -17.55 |
YTD | 29.51 |
4 Week | -9.84 |
12 Week | -20.26 |
YTD | 7.20 |
Shares Outstanding (millions) | 95.37 |
Market Capitalization (millions) | 11,910.30 |
Short Ratio | NA |
Last Split Date | 7/12/2012 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 85.88 |
Trailing 12 Months | 154.18 |
PEG Ratio | NA |
vs. Previous Year | 125.93% |
vs. Previous Quarter | -81.58% |
vs. Previous Year | 38.93% |
vs. Previous Quarter | -12.22% |
Price/Book | 10.96 |
Price/Cash Flow | NA |
Price / Sales | 7.91 |
6/30/24 | 5.32 |
3/31/24 | 2.20 |
12/31/23 | -18.97 |
6/30/24 | 1.50 |
3/31/24 | 0.58 |
12/31/23 | -4.65 |
6/30/24 | 3.90 |
3/31/24 | 4.05 |
12/31/23 | 3.95 |
6/30/24 | 3.19 |
3/31/24 | 3.44 |
12/31/23 | 3.45 |
6/30/24 | 3.24 |
3/31/24 | 1.31 |
12/31/23 | -11.74 |
6/30/24 | 3.14 |
3/31/24 | 1.20 |
12/31/23 | -43.11 |
6/30/24 | 4.13 |
3/31/24 | 2.43 |
12/31/23 | -41.83 |
6/30/24 | 11.40 |
3/31/24 | 10.17 |
12/31/23 | 9.19 |
6/30/24 | 0.49 |
3/31/24 | 0.57 |
12/31/23 | 0.60 |
6/30/24 | 1.05 |
3/31/24 | 1.18 |
12/31/23 | 1.32 |
6/30/24 | 51.31 |
3/31/24 | 54.12 |
12/31/23 | 56.86 |